|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,496.00 GBX | -4.96% |
|
-9.93% | -3.48% |
| Jul. 14 | Where would AI lead Pharma in the long run? |  |
| Jul. 10 | Thymoorgan Pharmazie Recalls Gemcitabine Injection Due To Temperature Abuse | CI |
| Market Cap | 4.22B 3.68B 3.41B 3.15B 5.93B 405B 6.03B 40.62B 15.94B 198B 15.84B 15.49B 683B | P/E 2026 * |
10.7x | P/E 2027 * | 9.68x |
|---|---|---|---|---|---|
| Enterprise Value | 5.69B 4.97B 4.59B 4.24B 7.99B 546B 8.14B 54.79B 21.5B 267B 21.36B 20.89B 921B | EV / Sales 2026 * |
1.64x | EV / Sales 2027 * | 1.53x |
| Free-Float |
63.72% | Yield 2026 * |
4.16% | Yield 2027 * | 4.4% |
Last Transcript: Hikma Pharmaceuticals PLC
| 1 day | -4.96% | ||
| 1 week | -9.93% | ||
| Current month | -1.58% | ||
| 1 month | +1.08% | ||
| 3 months | +11.64% | ||
| 6 months | -4.53% | ||
| Current year | -3.48% |
| 1 week | 1,490 |  | 1,658 |
| 1 month | 1,420 | | 1,762 |
| Current year | 1,187 | | 1,762 |
| 1 year | 1,187 | | 2,052 |
| 3 years | 1,187 | | 2,360 |
| 5 years | 1,174.5 | | 2,703 |
| 10 years | 814.2 | | 2,768 |
| Manager | Title | Age | Since |
|---|---|---|---|
Said Darwazah
CEO | Chief Executive Officer | 69 | 2025-11-30 |
Areb Kurdi
DFI | Director of Finance/CFO | - | 2026-02-25 |
| Chief Tech/Sci/R&D Officer | 64 | 2026-02-25 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 69 | 2005-10-13 | |
Khalid Nabilsi
BRD | Director/Board Member | 54 | 2025-12-14 |
Said Darwazah
CHM | Chairman | 69 | 2014-05-14 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| May. 31 | Sell | Investor Relations Manager | -26,558 | 0.0124% | ||
| May. 31 | Fiscal year | Chief Executive Officer | 91,812 | 0.0427% | ||
| May. 31 | Fiscal year | Investor Relations Manager | 11,664 | 0.0054% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.96% | -9.93% | -24.25% | -17.35% | 4.43B | |
| -2.48% | -6.72% | +44.19% | +156.43% | 1,054B | |
| -1.52% | -5.01% | +61.87% | +58.79% | 621B | |
| -1.30% | -3.88% | +27.81% | +79.97% | 438B | |
| -1.12% | -3.68% | +26.89% | +20.58% | 325B | |
| -1.73% | -3.45% | +26.95% | +44.09% | 281B | |
| -1.95% | -13.92% | +15.96% | +19.76% | 262B | |
| -1.45% | -2.37% | -27.87% | -39.87% | 219B | |
| -1.44% | -3.49% | +19.60% | +56.20% | 195B | |
| -1.04% | -4.63% | +16.01% | +68.47% | 163B | |
| Average | -1.61% | -4.73% | +18.72% | +44.71% | 356.06B | |
| Weighted average by Cap. | -0.90% | -4.78% | +33.09% | +76.93% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.46B 3.02B 2.8B 2.58B 4.86B 332B 4.95B 33.34B 13.08B 163B 13B 12.71B 561B | 3.62B 3.16B 2.92B 2.7B 5.09B 348B 5.18B 34.86B 13.68B 170B 13.59B 13.29B 586B |
| Net income | 405M 354M 327M 302M 569M 38.88B 579M 3.9B 1.53B 19.04B 1.52B 1.49B 65.55B | 443M 387M 358M 330M 622M 42.51B 633M 4.26B 1.67B 20.82B 1.66B 1.63B 71.68B |
| Net Debt | 1.47B 1.29B 1.19B 1.1B 2.07B 141B 2.1B 14.17B 5.56B 69.18B 5.52B 5.4B 238B | 1.31B 1.15B 1.06B 981M 1.85B 126B 1.88B 12.67B 4.97B 61.84B 4.94B 4.83B 213B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-14 | GBX 1,496.00 | -4.96% | 928,305 |
| 26-07-13 | GBX 1,574.00 | -0.63% | 987,734 |
| 26-07-10 | GBX 1,584.00 | -1.92% | 816,804 |
| 26-07-09 | GBX 1,615.00 | -1.04% | 1,977,692 |
| 26-07-08 | GBX 1,632.00 | -1.75% | 2,010,506 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- HIK Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
